- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02781740
Effects of Suboptimal CPAP Therapy on Symptoms of Obstructive Sleep Apnoea
Effects of Suboptimal Use of CPAP Therapy on Symptoms of Obstructive Sleep Apnoea
Obstructive sleep apnoea (OSA) is a highly prevalent sleep-related breathing disorder. The most effective treatment for OSA is continuous positive airway pressure (CPAP). CPAP therapy has been shown to significantly reduce subjective sleepiness and blood pressure in patients with symptomatic OSA. Its effectiveness tends to depend on its nightly usage and a commonly held view is that CPAP should be used for at least 4h/night. However, previous studies have estimated that a considerable proportion of CPAP users fail to achieve this. In addition, there is inadequate evidence to support this apparent threshold effect and so it is unclear whether such patients actually benefit from treatment or whether they could be withdrawn from CPAP, thus substantially reducing health care costs, or encouraged to increase their nightly usage of CPAP.
The aim of the proposed project is to study the effect of CPAP withdrawal on subjective sleepiness in OSA patients using CPAP for less than 4h/night on average. We hypothesize that two-week CPAP withdrawal in patients with 3-4h/night use will lead to a return of OSA-related symptoms. This trial will better establish the minimum level of CPAP adherence which could generally be regarded as effective in reducing OSA-related symptoms.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Zurich, Switzerland, 8091
- Pulmonary Division, University Hospital Zurich
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Objectively confirmed OSA (at the time of original diagnosis) with an oxygen desaturation index (ODI, ≥4% dips) of ≥15/h and an ESS of >10.
- Currently ≥15/h oxygen desaturations (≥4% dips) during an ambulatory nocturnal pulse oximetry performed at the end of a 4-night period without CPAP.
- Eligible patients must have been treated with CPAP for more than 12 months with a mean compliance between 3 and 4h/night. Apnoea-hypopnoea index (AHI) must be less than 10 with treatment (according to CPAP machine download data).
Exclusion Criteria:
- Previous ventilatory failure (awake PaO2<9.0kPa or arterial PaCO2>6kPa).
- Unstable, untreated coronary or peripheral artery disease, severe arterial hypertension (>180/110mmHg).
- Previously diagnosed with Cheyne-Stokes breathing.
- Current professional driver.
- Age < 20 or > 75 years at trial entry.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: CPAP therapy
Continuation of the already established CPAP therapy.
|
|
Sham Comparator: Sham CPAP therapy
Sham-CPAP is achieved by setting the CPAP machine to the lowest pressure, insertion of a flow-restricting connector at the machine outlet, and insertion of six extra holes in the collar of the main tubing at the end of the mask to allow air escape and to prevent rebreathing of CO2.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Epworth Sleepiness Scale (ESS)
Time Frame: Change from baseline in ESS after 2 weeks of CPAP or sham-CPAP respectively.
|
Standard, well-established Epworth questionnaire.
Score values between 0 and 24 represent severity of daytime sleepiness.
|
Change from baseline in ESS after 2 weeks of CPAP or sham-CPAP respectively.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Apnoea-Hypopnoea Index (AHI)
Time Frame: Change from baseline in AHI after 2 weeks of CPAP or sham-CPAP respectively.
|
AHI acquired non-invasively by respiratory polygraphy at baseline and after 2 weeks.
Measured in events per hour it represents severity of sleep apnoea.
|
Change from baseline in AHI after 2 weeks of CPAP or sham-CPAP respectively.
|
Oxygen Desaturation Index (ODI)
Time Frame: Change from baseline in ODI after 2 weeks of CPAP or sham-CPAP respectively.
|
ODI acquired non-invasively by respiratory polygraphy at baseline and after 2 weeks.
Measured in events per hour it represents severity of sleep apnoea.
|
Change from baseline in ODI after 2 weeks of CPAP or sham-CPAP respectively.
|
Mean CPAP usage time
Time Frame: Measured at baseline and after 2 weeks of CPAP or sham-CPAP respectively.
|
Acquired automatically by the CPAP/sham-CPAP devices over the course of 2 weeks.
Measured in hours per night it represents treatment adherence.
|
Measured at baseline and after 2 weeks of CPAP or sham-CPAP respectively.
|
Heart rate
Time Frame: Change from baseline in heart rate after 2 weeks of CPAP or sham-CPAP respectively.
|
Resting heart rate acquired non-invasively during wakefulness following respiratory polygraphies at baseline and after 2 weeks.
Measured in beats per minute (bpm).
|
Change from baseline in heart rate after 2 weeks of CPAP or sham-CPAP respectively.
|
Mean blood pressure
Time Frame: Change from baseline in mean blood pressure after 2 weeks of CPAP or sham-CPAP respectively.
|
Mean resting blood pressure acquired non-invasively during wakefulness following respiratory polygraphies at baseline and after 2 weeks.
Measured in mmHg.
|
Change from baseline in mean blood pressure after 2 weeks of CPAP or sham-CPAP respectively.
|
Fatigue Severity Scale (FSS)
Time Frame: Change from baseline in FSS after 2 weeks of CPAP or sham-CPAP respectively.
|
Standard, well-established FSS questionnaire.
Score values between 7 and 63 represent severity of daytime fatigue.
|
Change from baseline in FSS after 2 weeks of CPAP or sham-CPAP respectively.
|
Quality of life as assessed in Short Form 36 (SF-36)
Time Frame: Change from baseline in SF-36 after 2 weeks of CPAP or sham-CPAP respectively.
|
Standard, well-established 36-item patient-reported survey of patient general health status.
|
Change from baseline in SF-36 after 2 weeks of CPAP or sham-CPAP respectively.
|
Quality of life as assessed in Functional Outcomes of Sleep Questionnaire 10 (FOSQ-10)
Time Frame: Change from baseline in FOSQ-10 after 2 weeks of CPAP or sham-CPAP respectively.
|
FOSQ-10 is a standard, well-established 10-item patient-reported survey of impact of disorders of excessive sleepiness on activities of daily living.
|
Change from baseline in FOSQ-10 after 2 weeks of CPAP or sham-CPAP respectively.
|
Psychomotor vigilance as measured through the Oxford Sleep Resistance test (OSLER).
Time Frame: Change from baseline in OSLER after 2 weeks of CPAP or sham-CPAP respectively.
|
OSLER is a standard test consisting of one to three 40-min sessions assessing the patients ability of performing a repetitive task.
The OSLER error index measured in events per hour correlates statistically with sleep latency.
|
Change from baseline in OSLER after 2 weeks of CPAP or sham-CPAP respectively.
|
Psychomotor vigilance as measured through the Multiple Unprepared Reaction Time Test (MURT)
Time Frame: Change from baseline in MURT after 2 weeks of CPAP or sham-CPAP respectively.
|
MURT is a standard test consisting of two 10-min sessions assessing the patient's alertness.
The MURT time measured in milliseconds represents the patients reaction time and correlates with sleep latency.
|
Change from baseline in MURT after 2 weeks of CPAP or sham-CPAP respectively.
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KEK-ZH-Nr.: 2016-00332
- 2015-MD-0037 (Other Identifier: Swissmedic)
- CIV-15-12-014246 (Other Identifier: EUDAMED)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sleep Apnea, Obstructive
-
LivaNovaRecruitingApnea | Obstructive Sleep Apnea | OSA | Apnea, Obstructive | Apnea+Hypopnea | Apnea, Obstructive Sleep | Hypopnea, SleepUnited States
-
Mauro ManconiCompletedObstructive Sleep Apnea Syndrome | Sleep Apnea, Obstructive | Obstructive Sleep Apnea | OSA | Apnea, Obstructive | OSAHSwitzerland
-
University of California, Los AngelesRecruiting
-
Brigham and Women's HospitalCompletedObstructive Sleep Apnea (OSA)United States
-
State Budgetary Healthcare Institution, National...RecruitingObstructive Sleep Apnea | Obstructive Sleep Apnea-hypopnea | Obstructive Sleep Apnea-hypopnea SyndromeRussian Federation
-
The Hospital for Sick ChildrenCompleted
-
Cryosa, Inc.Active, not recruitingObstructive Sleep Apnea of AdultPanama, Paraguay
-
State Key Laboratory of Respiratory DiseaseCompletedObstructive Sleep Apnea of AdultChina
-
Somnics, Inc.UnknownObstructive Sleep Apnea of AdultTaiwan
-
ApnimedCompletedOSA - Obstructive Sleep ApneaUnited States
Clinical Trials on Continous Positive Air Pressure Device
-
ResMedCompletedObstructive Sleep ApneaUnited Kingdom
-
Mirjana Grebenar CerkezRecruitingObstructive Sleep ApneaCroatia
-
University of Colorado, DenverEnrolling by invitationHypoxemia | Altitude HypoxiaUnited States
-
Hospital of South West JutlandCompletedRespiratory Syncytial Virus BronchiolitisDenmark
-
Nagoya UniversityCompleted
-
Oregon Health and Science UniversityCompletedRespiratory Distress Syndrome | Bronchopulmonary DysplasiaUnited States
-
King Abdulaziz UniversityRecruitingObstructive Sleep ApneaSaudi Arabia
-
Mansoura UniversityRecruiting
-
Vastra Gotaland RegionActive, not recruitingHeart Failure | Stroke | Hypertension | Obstructive Sleep Apnea | Treatment Compliance | Death, CardiacSweden
-
University of MichiganNational Heart, Lung, and Blood Institute (NHLBI); Michigan Technological UniversityCompletedSleep Apnea Syndromes | Sleep Apnea, Obstructive | Disorders of Excessive Somnolence | Attention Deficit Disorder With Hyperactivity | Child Behavior DisordersUnited States